SEC For	m 4																		
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					MENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* Guse Kyle						2. Issuer Name and Ticker or Trading Symbol ATOSSA THERAPEUTICS, INC. [ATOS]								eck all applic Director	able)	1		o Issuer % Owner ther (specify	
(Last) (First) (Middle) C/O ATOSSA THERAPEUTICS, INC. 107 SPRING STREET						3. Date of Earliest Transaction (Month/Day/Year) 03/02/2023								A below) below) below) CFO, Gen Counsel and Secretary					
(Street) SEATTLE WA 98104					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																			
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/I)				actio				a, 3. Trans Code	action	4. Securi	ties Acquir	ed (A) or str. 3, 4 and	5. Amount of		Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Table II - I								osed of, converti	, or Ben		<u> </u>	nu +)	<u> </u>	I		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\	Co	ansao ode (l		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (right to buy)	\$0.72	03/02/2023			A		557,900		(1)	(03/02/2033	Common Stock	557,900	\$0	557,9	00	D		

Explanation of Responses:

1. The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date.

<u>/s/ Kyle Guse</u>

** Signature of Reporting Person

03/06/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.